Johnson & Johnson (JNJ) Raised to Buy at Vetr
Johnson & Johnson (NYSE:JNJ) was upgraded by equities research analysts at Vetr from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday. The firm presently has a $152.28 price objective on the stock. Vetr‘s price objective would indicate a potential upside of 7.37% from the company’s current price.
A number of other brokerages also recently weighed in on JNJ. Wells Fargo & Co restated an “outperform” rating and set a $160.00 target price (up from $155.00) on shares of Johnson & Johnson in a report on Friday, January 12th. Credit Suisse Group set a $154.00 target price on shares of Johnson & Johnson and gave the stock a “hold” rating in a report on Monday. Royal Bank of Canada restated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, January 9th. Citigroup boosted their target price on shares of Johnson & Johnson from $140.00 to $149.00 and gave the stock a “buy” rating in a report on Monday, October 23rd. Finally, Zacks Investment Research downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Tuesday, December 12th. Four investment analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $146.01.
Shares of Johnson & Johnson (NYSE JNJ) traded down $6.31 on Tuesday, reaching $141.83. 17,449,593 shares of the company were exchanged, compared to its average volume of 6,160,000. The firm has a market capitalization of $381,030.00, a P/E ratio of 24.62, a price-to-earnings-growth ratio of 2.76 and a beta of 0.80. Johnson & Johnson has a fifty-two week low of $110.76 and a fifty-two week high of $148.32. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32.
A number of hedge funds have recently added to or reduced their stakes in the business. Harding Loevner LP bought a new stake in shares of Johnson & Johnson in the second quarter valued at about $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its position in shares of Johnson & Johnson by 29.9% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after acquiring an additional 200 shares during the period. Mountain Capital Investment Advisors Inc bought a new stake in shares of Johnson & Johnson in the second quarter valued at about $124,000. Cerebellum GP LLC bought a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $166,000. Finally, Shine Investment Advisory Services Inc. bought a new stake in shares of Johnson & Johnson in the second quarter valued at about $177,000. 65.72% of the stock is owned by hedge funds and other institutional investors.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.